Shaker Investments LLC OH cut its holdings in Insulet Co. (NASDAQ:PODD) by 1.6% during the 4th quarter, HoldingsChannel reports. The fund owned 79,170 shares of the medical instruments supplier’s stock after selling 1,290 shares during the quarter. Insulet accounts for approximately 3.6% of Shaker Investments LLC OH’s holdings, making the stock its 3rd largest position. Shaker Investments LLC OH’s holdings in Insulet were worth $5,463,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Cerebellum GP LLC acquired a new position in shares of Insulet in the fourth quarter valued at about $122,000. Equitec Specialists LLC acquired a new position in shares of Insulet in the fourth quarter valued at about $145,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Insulet in the fourth quarter valued at about $188,000. Diversified Trust Co acquired a new position in shares of Insulet in the fourth quarter valued at about $218,000. Finally, RNC Capital Management LLC acquired a new position in shares of Insulet in the second quarter valued at about $225,000.

PODD has been the topic of several research reports. Wedbush restated a “buy” rating and issued a $65.00 price target (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “hold” rating and set a $68.00 price target on the stock in a research note on Thursday, October 12th. Leerink Swann restated an “outperform” rating and issued a $74.00 price target (up from $65.00) on shares of Insulet in a research note on Thursday, October 12th. Robert W. Baird set a $65.00 price target on shares of Insulet and gave the company a “buy” rating in a research note on Friday, October 13th. Finally, Canaccord Genuity upgraded shares of Insulet from a “hold” rating to a “buy” rating and upped their price target for the company from $50.00 to $65.00 in a research note on Wednesday, November 1st. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $62.53.

Shares of Insulet Co. (NASDAQ:PODD) opened at $73.92 on Tuesday. The stock has a market cap of $4,412.96, a PE ratio of -147.84 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet Co. has a one year low of $38.43 and a one year high of $78.65.

In other news, Director James C. Mullen acquired 2,500 shares of Insulet stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $67.45 per share, for a total transaction of $168,625.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/02/06/shaker-investments-llc-oh-has-5-46-million-stake-in-insulet-co-podd.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.